For patients with active lupus nephritis, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody plus standard ...

Kiniksa will now focus its development efforts on the IL-1 blocker KPL-387, which it is testing for recurrent pericarditis ...

Discover how next-generation kinase inhibitors are transforming clinical therapy byovercoming resistance and enhancing ...

Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

With early diagnosis of Alzheimer's disease comes the possibility of treatment to not only help manage symptoms but also slow ...

Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 –– KPL-387 Phase 1 single ascending dose ...

Rapid Enrollment and Dosing of First Patients Encouraging and Underscores Unmet Need for Better Treatment Options for Alzheimer’s Disease ...

The CDC said in a statement on Monday that it does not believe the new coronavirus found in bats poses a concern to public health currently.

Researchers have discovered a virus that could enter human cells in a similar way to COVID-19. But they caution it's much ...